Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS

Article English OPEN
Saintas, Emily ; Abrahams, Liam ; Ahmed, Gulshan T ; Ajakaiye, Anu-Oluwa M ; AlHumaidi, Abdulaziz S H A M ; Ashmore-Harris, Candice ; Clark, Iain ; Dura, Usha K ; Fixmer, Carine N ; Ike-Morris, Chinedu ; Mato Prado, Mireia ; Mccullough, Danielle ; Mishra, Shishir ; Schoeler, Katia M U ; Timur, Husne ; Williamson, Maxwell D C ; Alatsatianos, Markella ; Bahsoun, Basma ; Blackburn, Edith ; Hogwood, Catherine E.M. ; Lithgow, Pamela E ; Rowe, Michelle L. ; Yiangou, Lyto ; Rothweiler, Florian ; Cinatl jr, Jindric ; Zehner, Richard ; Baines, Anthony J. ; Garrett, Michelle D. ; Gourlay, Campbell W. ; Griffin, Darren K. ... view all 40 authors (2017)
  • Publisher: Public Library of Science
  • Journal: (vol: 12)
  • Related identifiers: doi: 10.1371/journal.pone.0172140, pmc: PMC5305101
  • Subject: Cancer Treatment | Cultured Tumor Cells | Research Article | DNA damage | Protein Kinases | Enzymes | DNA repair | Tyrosine Kinases | Oncology | Chemical Elements | Neuroblastoma Cells | Platinum | Physical sciences | Genetics | Proteins | DNA | Physics | Phosphorylation | Chemistry | Biology and Life Sciences | Research and Analysis Methods | Post-Translational Modification | Nucleic acids | Enzymology | Ultraviolet radiation | Electromagnetic radiation | Light | Ultraviolet C | Biochemistry | Biological Cultures | Cell Cultures | Medicine and Health Sciences | RM | Nucleotide Excision Repair
    • ddc: ddc:610
    mesheuropmc: neoplasms

The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line SK-N-AS that was adapted to growth in the presence of 4000 ng/mL oxaliplatin (SK-N-ASrOXALI4000). SK-N-ASrOXALI4000 cells displayed enhanced chromosomal aberrations compared to SK-N-AS, as indicated by 24-chromosome fluorescence in situ hybridisation. Moreover, SK-N-ASrOXALI4000 cells were resistant not only to oxaliplatin but also to the two other commonly used anti-cancer platinum agents cisplatin and carboplatin. SK-N-ASrOXALI4000 cells exhibited a stable resistance phenotype that was not affected by culturing the cells for 10 weeks in the absence of oxaliplatin. Interestingly, SK-N-ASrOXALI4000 cells showed no cross resistance to gemcitabine and increased sensitivity to doxorubicin and UVC radiation, alternative treatments that like platinum drugs target DNA integrity. Notably, UVC-induced DNA damage is thought to be predominantly repaired by nucleotide excision repair and nucleotide excision repair has been described as the main oxaliplatin-induced DNA damage repair system. SK-N-ASrOXALI4000 cells were also more sensitive to lysis by influenza A virus, a candidate for oncolytic therapy, than SK-N-AS cells. In conclusion, we introduce a novel oxaliplatin resistance model. The oxaliplatin resistance mechanisms in SK-N-ASrOXALI4000 cells appear to be complex and not to directly depend on enhanced DNA repair capacity. Models of oxaliplatin resistance are of particular relevance since research on platinum drugs has so far predominantly focused on cisplatin and carboplatin.
  • References (60)
    60 references, page 1 of 6

    1. Gupta GP, Massague´ J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-695. doi: 10. 1016/j.cell.2006.11.001 PMID: 17110329

    2. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012; 12: 39-50.

    3. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13: 714-726. doi: 10.1038/nrc3599 PMID: 24060863

    4. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010; 10: 241-253. doi: 10.1038/nrc2820 PMID: 20300105

    5. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notchand hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22: 373-388. doi: 10.1016/j.ccr. 2012.07.016 PMID: 22975379

    6. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013; 3: 1020-1029. doi: 10.1158/2159-8290.CD-13-0226 PMID: 23779130

    7. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013; 3: 1030-1043. doi: 10.1158/2159-8290.CD-13-0142 PMID: 23842682

    8. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol. 2014; 87: 381-389. doi: 10.1016/j.bcp.2013.11.013 PMID: 24291778

    9. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science, 2014; 346: 1480-1486. doi: 10.1126/science.1254721 PMID: 25394791

    10. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010; 362: 2202-2211. doi: 10.1056/ NEJMra0804577 PMID: 20558371

  • Related Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark